Dutta, Binita
Huys, Isabelle
Vulto, Arnold G. http://orcid.org/0000-0002-8439-2800
Simoens, Steven http://orcid.org/0000-0002-9512-2005
Funding for this research was provided by:
KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity
Article History
First Online: 2 December 2019
Compliance with Ethical Standards
:
: This manuscript is supported by the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL).
: SS, IH, and AGV have conducted biosimilar research sponsored by Hospira (now Pfizer). SS was involved in a stakeholder roundtable on biosimilars sponsored by Amgen, Pfizer, and MSD, and has participated in an advisory board meeting for Pfizer. SS currently works with Pfizer, and works with Mundipharma and Celltrion as a consultant, to carry out biosimilar research. AGV is involved in consulting, advisory work, and speaking engagements for a number of companies, including AbbVie, Accord, Amgen, Biogen, EGA/Medicines for Europe, Fresenius-Kabi, Pfizer/Hospira, Mundipharma, Roche, and Sandoz.